In a previous study, using clinical data, we demonstrated that BRCA1/2‐mutated patient tumours respond better to combination PARP inhibition and chemotherapy compared to BRCA‐wildtype patient tumours [6]. This evidence concerns the gene BRCA1 and neoplasm.